In the BioHarmony Drug Report Database

"Preview" Icon

Ixabepilone

Ixempra (ixabepilone) is a small molecule pharmaceutical. Ixabepilone was first approved as Ixempra on 2007-10-16. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against tubulin beta chain. In addition, it is known to target tubulin–tyrosine ligase. Ixempra’s patents are valid until 2024-08-21 (FDA).

 

Trade Name

 

Ixempra
 

Common Name

 

ixabepilone
 

ChEMBL ID

 

CHEMBL1201752
 

Indication

 

breast neoplasms
 

Drug Class

 

Image (chem structure or protein)

Ixabepilone structure rendering